Shots:
- IDEAYA has entered an exclusive licensing agreement granting Servier global regulatory and commercial rights to darovasertib, while retaining all the US rights
- IDEAYA & Servier will co-develop darovasertib & share costs, with Servier leading regulatory & commercial efforts worldwide excl. the US, in exchange for $210M upfront, ~$100M on approval, ~$220M in commercial milestones, with double-digit royalties on sales outside the US
- Darovasertib is in P-II/III trial with crizotinib for 1L HLA-A2-negative metastatic UM (mPFS data expected in late 2025–Q1’26) & a P-III study as a neoadj. therapy for primary UM; a P-III trial is planned for 2026 to assess it in adj. setting for both HLA-A2 HLA-A2 subgroups
Ref: Servier| Image: IDEAYA & Servier| Press Release
Related News:- IDEAYA Enters Into an Additional Clinical Study Collaboration and Supply Agreement with Gilead Sciences
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
